Immunophenotypic changes following menin inhibition in acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: Immunophenotypic changes following menin inhibition in acute myeloid leukemia.
Authors: Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. sloghavi@mdanderson.org., Farhat A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jamison TJ; Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., El Hajjar G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Quesada AE; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bazinet A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cuglievan B; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. gcissa@mdanderson.org.
Source: Leukemia [Leukemia] 2026 Jun; Vol. 40 (6), pp. 1142-1150. Date of Electronic Publication: 2026 Mar 11.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-026-02905-6